Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Cash from Financing Activities (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Cash from Financing Activities for 9 consecutive years, with $8000.0 as the latest value for Q4 2024.

  • Quarterly Cash from Financing Activities fell 99.76% to $8000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $46.8 million through Dec 2024, up 109.54% year-over-year, with the annual reading at $86.3 million for FY2025, 84.56% up from the prior year.
  • Cash from Financing Activities for Q4 2024 was $8000.0 at SELLAS Life Sciences, down from $19.7 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $26.6 million in Q1 2024, with the low at -$29000.0 in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $7.2 million, with a median of $2.6 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 40121.28% in 2023, while the deepest fall reached 100.13% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $23.7 million in 2020, then crashed by 99.79% to $50000.0 in 2021, then soared by 1758.0% to $929000.0 in 2022, then skyrocketed by 264.48% to $3.4 million in 2023, then plummeted by 99.76% to $8000.0 in 2024.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $8000.0, $19.7 million, and $414000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.